37619-17-3

Upstream product

• 106-43-4 para-chlorotoluene 
• 134-20-3 2-carbomethoxyaniline 
• 874-60-2 4-methyl-benzoyl chloride 

Downstream Products

• 1072106-85-4 C₁₆H₁₄ClNO₂ 
• 147876-37-7 4-bromomethyl-2'-methoxycarbonylbenzanilide 
• 85094-64-0 2-(4-methylphenyl)-4H-3,1-benzothiazin-4-one 
• 18818-41-2 2-(4-methylphenyl)-4(3H)-quinazolinone 
• 18600-54-9 2-(4-methylphenyl)-4H-3,1-benzoxazin-4-one 
• 53628-15-2 (methyl-4 phenyl)-2 benzothiazine-3,1 thione-4 
• 52910-88-0 N-(2-carbamoylphenyl)-4-methylbenzamide 

Relevant academic research and scientific papers

NOVEL BIARYLAMIDE DERIVATIVE AND COMPOSITIONS CONTAINING THE DERIVATIVE AS AN ACTIVE INGREDIENT

The present invention relates to a novel biarylamide derivative and a pharmaceutical composition or a cosmetic composition comprising the same as an active ingredient. More particularly, the present invention relates to a novel biarylamide derivative, a pharmaceutical composition or a cosmetic composition for preventing or treating a pigmentation disorder caused by an abnormal excess of melanin or a disease caused by melanocyte hyperplasia comprising the same as an active ingredient. The biarylamide derivative of the present invention inhibits melanin production and thus inhibits melanocyte hyperplasia. Therefore, a cosmetic composition comprising the biarylamide is excellent in a whitening effect, and a pharmaceutical composition comprising the biarylamide is effective in the prevention or treatment of pigmentation disorders of skin such as lentigo, melasma, freckle, etc. and malignant melanoma.

Identification of a potent and noncytotoxic inhibitor of melanin production

On the basis of a hit from random screening, biaryl amide derivatives were prepared in a combinatorial manner via parallel solution-phase synthesis, and their effects on melanocytes were investigated to discover new effective skin depigmenting agents. Amo

An efficient synthesis of 2,3-diaryl (3H)-quinazolin-4-ones via imidoyl chlorides

A practical and efficient three step synthetic route to 2,3-diaryl (3H)-quinazolin-4-ones has been developed. The key step involves microwave-assisted condensation of an imidoyl chloride with an aryl amine. This methodology affords the products cleanly and in high yields.

The evaluation and structure-activity relationships of 2-benzoylaminobenzoic esters and their analogues as anti-inflammatory and anti-platelet aggregation agents

Forty-seven 2-benzoylaminobenzoic esters were synthesized and evaluated in anti-platelet aggregation, inhibition of superoxide anion generation, and inhibition of neutrophil elastase release assays. Most 2-benzoylamino-4-chlorobenzoic acid derivatives showed selective inhibitory effects on arachidonic acid (AA)-induced platelet aggregation. Among them, compounds 6b and 7b exhibited more potent inhibitory effects (ca. 200-fold) than aspirin. Additionally, compounds 1a and 5a showed strong inhibitory effects on neutrophil superoxide generation with IC50 values of 0.65 and 0.17 μM, respectively. However, compounds 6d and 6e exhibited dual inhibitory effects on platelet aggregation and neutrophil elastase (NE) release; therefore, these two compounds may be new leads for development as anti-inflammatory and anti-platelet aggregatory agents.